The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
Adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy
Breast Cancer
Early Breast Cancer
HER2+
KATHERINE
A
ADJUSTMENTS
FINAL SCORE
F1
1
Pembrolizumab
-
Placebo
Adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma and who have undergone complete resection
Melanoma
Cutaneous Melanoma
-
KEYNOTE-716
A
ADJUSTMENTS
FINAL SCORE
F1
1
Nivolumab
Platinum-doublet ChT
Platinum-doublet ChT
Treatment of adult patients with resectable non-small cell lung cancer in the neoadjuvant setting
Thoracic Malignancies
Non-small-cell Lung Cancer
-
CHECKMATE-816
A
ADJUSTMENTS
FINAL SCORE
F1
1
Selpercatinib
-
Single arm (Phase I/II)
Treatment of adults with advanced RET fusion positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor
Thoracic Malignancies
Non-small-cell Lung Cancer
RET fusion-positive
LIBRETTO-001
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Trastuzumab deruxtecan
-
Trastuzumab emtansine (T-DM1)
Treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti HER2 based regimens
Breast Cancer
Breast Cancer
HER2+
DESTINY-Breast03
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Tepotinib
-
Single arm (Phase II)
For adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations
Thoracic Malignancies
Non-small-cell Lung Cancer
METex14 skipping
VISION
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Nivolumab
-
ChT
First-line treatment of adult patients with advance or metastatic oesophageal squamous cell carcinoma in combination with fluoropyrimidine and platinum-based combination ChT
Gastrointestinal Cancers
Oesophageal Cancer
-
CheckMate 648
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Nivo/Ipi (nivolumab and ipilimumab)
-
ChT
First-line treatment of adult patients with advance or metastatic oesophageal squamous cell carcinoma in combination with ipilimumab
Gastrointestinal Cancers
Oesophageal Cancer
-
CheckMate 648
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Dab/Tram (dabrafenib and trametinib)
-
Single arm (Phase II)
For the treatment of adult and pediatric patients ≥ 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options
Brain Tumours
Glioma (high grade)
BRAF V600E
ROAR
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Dab/Tram (dabrafenib and trametinib)
-
Single arm (Phase II)
For the treatment of adult and pediatric patients ≥ 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options
Brain Tumours
Glioma (low grade)
BRAF V600E
ROAR
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Treatment Setting
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
esmo.mcbs.table.heading.visualisation
esmo.mcbs.table.heading.visualisation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.